Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection-Reference-Cited by-同舟云学术

Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection

Published:2022-02-23 Issue:1 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Barbosa Juliana Magalhães Chaves¹,Pedra Rezende Yasmin¹,de Melo Tatiana Galvão²,de Oliveira Gabriel¹,Cascabulho Cynthia Machado³,Pereira Evelyn Nunes Goulart da Silva⁴,Daliry Anissa⁴^ORCID,Salem Kelly Salomão¹^ORCID

Affiliation:

1. Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil

2. Laboratório de Ultraestrutura Celular, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil

3. Laboratório de Inovações em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil

4. Laboratório de Investigação Cardiovascular, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil

Abstract

Chagas disease affects approximately 6 to 7 million people worldwide, with cardiomyopathy being the clinical manifestation that most commonly leads to patient death. The etiological treatment of Chagas disease is limited to drugs (benznidazole and nifurtimox) with relatively high toxicity and therapeutic failures.

Funder

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Fundação Oswaldo Cruz

MCTI | Conselho Nacional de Desenvolvimento Científico e Tecnológico

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.01852-21

Reference69 articles.

1. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem

2. Chagas disease

3. World Health Organization. 2013. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected tropical diseases. World Health Organization, Geneva, Switzerland.

4. Developments in the management of Chagas cardiomyopathy

5. Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Importance of CD40/CD40L dyad in the course of infection with Trypanosoma cruzi: Impact of its inhibition;Microbial Pathogenesis;2023-10

2. Preclinical data do not support the use of amiodarone or dronedarone as antiparasitic drugs for Chagas disease at the approved human dosing regimen;Frontiers in Tropical Diseases;2023-09-27

3. Nitazoxanide: A Drug Repositioning Compound with Potential Use in Chagas Disease in a Murine Model;Pharmaceuticals;2023-06-01

4. State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation;Research and Reports in Tropical Medicine;2023-06

5. Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in Trypanosoma cruzi-infected cardiac cells;Frontiers in Cellular and Infection Microbiology;2022-08-25